HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial.

AbstractBACKGROUND:
Fluoroquinolones are the most commonly used group of antimicrobials for the treatment of enteric fever, but no direct comparison between two fluoroquinolones has been performed in a large randomised trial. An open-label randomized trial was conducted to investigate whether gatifloxacin is more effective than ofloxacin in the treatment of uncomplicated enteric fever caused by nalidixic acid-resistant Salmonella enterica serovars Typhi and Paratyphi A.
METHODOLOGY AND PRINCIPAL FINDINGS:
Adults and children clinically diagnosed with uncomplicated enteric fever were enrolled in the study to receive gatifloxacin (10 mg/kg/day) in a single dose or ofloxacin (20 mg/kg/day) in two divided doses for 7 days. Patients were followed for six months. The primary outcome was treatment failure in patients infected with nalidixic acid resistant isolates. 627 patients with a median age of 17 (IQR 9-23) years were randomised. Of the 218 patients with culture confirmed enteric fever, 170 patients were infected with nalidixic acid-resistant isolates. In the ofloxacin group, 6 out of 83 patients had treatment failure compared to 5 out of 87 in the gatifloxacin group (hazard ratio [HR] of time to failure 0.81, 95% CI 0.25 to 2.65, p = 0.73). The median time to fever clearance was 4.70 days (IQR 2.98-5.90) in the ofloxacin group versus 3.31 days (IQR 2.29-4.75) in the gatifloxacin group (HR = 1.59, 95% CI 1.16 to 2.18, p = 0.004). The results in all blood culture-confirmed patients and all randomized patients were comparable.
CONCLUSION:
Gatifloxacin was not superior to ofloxacin in preventing failure, but use of gatifloxacin did result in more prompt fever clearance time compared to ofloxacin.
TRIAL REGISTRATION:
ISRCTN 63006567 (www.controlled-trials.com).
AuthorsSamir Koirala, Buddha Basnyat, Amit Arjyal, Olita Shilpakar, Kabina Shrestha, Rishav Shrestha, Upendra Man Shrestha, Krishna Agrawal, Kanika Deshpande Koirala, Sudeep Dhoj Thapa, Abhilasha Karkey, Sabina Dongol, Abhishek Giri, Mila Shakya, Kamal Raj Pathak, James Campbell, Stephen Baker, Jeremy Farrar, Marcel Wolbers, Christiane Dolecek
JournalPLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 7 Issue 10 Pg. e2523 ( 2013) ISSN: 1935-2735 [Electronic] United States
PMID24282626 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Ofloxacin
  • Gatifloxacin
Topics
  • Adolescent
  • Anti-Bacterial Agents (administration & dosage)
  • Child
  • Drug Resistance, Bacterial
  • Female
  • Fluoroquinolones (administration & dosage)
  • Gatifloxacin
  • Humans
  • Male
  • Nepal
  • Ofloxacin (administration & dosage)
  • Salmonella paratyphi A (drug effects, isolation & purification)
  • Salmonella typhi (drug effects, isolation & purification)
  • Treatment Failure
  • Typhoid Fever (drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: